Drug Profile
Olanzapine/samidorphan - Alkermes
Alternative Names: ALKS 33/olanzapine; ALKS-3831; LYBALVI; Olanzapine/ALKS 33; OLZ/SAM - Alkermes plc; Samidorphan/olanzapineLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Alkermes plc
- Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Mood stabilisers; Morphinans; Oxazepines; Phenanthrenes; Small molecules; Thiazepines
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Schizophrenia
- Phase III Psychotic disorders
Most Recent Events
- 26 Feb 2024 Alkermes has patent protection for olanzapine/samidorphan in USA (Prior to February 2024)
- 03 Jan 2024 Efficacy and adverse events data from phase III trial for Schizophrenia and Bipolar disorder released by Alkermes
- 06 Sep 2023 Alkermes completes a phase III trial for Schizophrenia and Bipolar disorder in, USA, Austria, Bulgaria, Ireland, Israel, Italy, South Korea, Poland, Puerto Rico, Russia, Serbia, Ukraine, United Kingdom (NCT03201757) (EudraCT2017-000918-36)